Navigation Links
KV Pharmaceutical Suspends Product Manufacturing, Shipping
Date:1/26/2009

ST. LOUIS, Jan. 26 /PRNewswire-FirstCall/ -- KV Pharmaceutical (NYSE: KVa/KVb) has voluntarily suspended the manufacturing and shipping of all of its products, other than certain products that it distributes but does not manufacture. The suspension began on January 22, 2009.

Additionally, the company will conduct a voluntary recall of most of its products. The scope and depth of the recall are currently under discussion with the U.S. Food and Drug Administration (FDA).

These actions are being taken in cooperation with the previously announced inspection by the FDA of the company's operations and inventory, which began in December. To resume shipments as quickly as possible, the company is working with a third-party consulting group, Lachman Consultant Services, Inc., to review manufacturing and packaging processes.

"The new leadership team at KV realizes that we are in a very challenging time for the company," said interim President and CEO David Van Vliet. "We are committed, however, to resolving these issues and resuming production as soon as possible by working closely with the FDA and the independent experts from Lachman Consultant Services."

KV expects these actions to have a material adverse effect on its financial condition, and as a result, may not be in compliance with one or more covenants included in a credit agreement with its lenders. As of December 31, 2008, the outstanding balance under this line of credit was approximately $30 million.

The company's Board of Directors has appointed a special committee consisting of the following members of the Board: Jean M. Bellin, Kevin S. Carlie, Terry B. Hatfield, Jonathon E. Killmer and Norman D. Schellenger. Mr. Hatfield, the Chairman of the Board, has been appointed to serve as the Chairman of the special committee. The special committee was formed in response to the initiation of a series of putative cla
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... San Jose, CA (PRWEB) , ... September 02, ... ... connectivity for Internet of Things, announces its latest addition to its screen mirroring ... the existing award-winning Splashtop Extended Wireless Display, which operates in local WIFI setting, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces ... a plus-size actress as the primary love interest in the film. The campaign is ... film, significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and ...
(Date:9/2/2015)... ... , ... Ericson is a noted speaker and educator in the field of ... Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) where she developed and ... serves as a CDI subject matter expert for a variety of HCPro and ACDIS ...
(Date:9/2/2015)... ... September 02, 2015 , ... A recent survey by Consumer Reports ... year and its negative impact on consumers. It was reported that 33% are paying ... paying as much as an extra $100 compared to last year. Among the drugs ...
Breaking Medicine News(10 mins):Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... data from a Phase 2 clinical trial of GVAX ... Johns Hopkins Sidney Kimmel Cancer Center. The trial ... GVAX after surgical resection of their tumor and adjuvant ... patients was previously reported to be 26.8 months, a ...
... end, even if it is all subtle, as in Canada ... pin down is more dangerous to mental health than ... living in Canada. ,"We found that the subtle ... such as symptoms of depression and anxiety," said lead author ...
... Annual Meeting of SNM, the world's largest society ... German researchers stated that early metabolic imaging with ... to chemotherapy for esophageal cancer. ,"This ... from early metabolic response assessment to clinical decision ...
... announced today that HHS has awarded a contract for $500 ... manufacture and deliver 20 million doses of a next generation ... would be recommended in the event of a smallpox outbreak ... immune systems. The full supply of the vaccine will be ...
... welcomed a new study to be published today in ... contribute to the steadily mounting evidence that undermines ... obesity. A report issued last Friday by the Federal ... Archives study found that "children do not currently see ...
... interim findings from its Phase II, multi-center clinical ... anthracycline currently in development for the treatment of ... indicate favorable interim results in terms of response ... current treatment standard, topotecan, in second-line treatment of ...
Cached Medicine News:Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 3Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 4Health News:Koreans in Canada Feel Put Down by Subtle Racism 2Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:New Studies: Commercials Aren't Making Kids Fat 2Health News:Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment 2
(Date:9/2/2015)... , Sept. 2, 2015 This ... studies the current and future prospects of the ... patient,s health and assists medical practitioners in deciding ... disease progression during treatment. Multi-parameter patient monitoring is ... chronic disease. Geriatric population is observed to be ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... is an X-linked disease, which generally affects the ... degeneration and weakness. The disease is caused due ... in the lack of production of dystrophin (a ... individuals. The lack of dystrophin weakens muscle function, ...
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
Breaking Medicine Technology:Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... helps provide protection to the exposed airway of ... lightweight making it ideal for active young children ... of heat and moisture recovery, it ensures patient ... and filters have ISO standard tapered ends to ...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... digital models cover the range from 2ul to ... Volume lock design prevents inadvertent volume change. ... grip. Whole pipette is autoclavable at 121C(250F). ... all polypropylene. Suitable for one-handed operation. ...
Medicine Products: